首页 | 本学科首页   官方微博 | 高级检索  
检索        

纤维蛋白原功能评价肺心病抗凝疗效的研究
引用本文:朱明霞,刘海亮,刘大鹰,周锦钢,钟燕,彭佳,陈锦平,李乃庆,李义华,李品蓉.纤维蛋白原功能评价肺心病抗凝疗效的研究[J].血栓与止血学,2007,13(6):261-263.
作者姓名:朱明霞  刘海亮  刘大鹰  周锦钢  钟燕  彭佳  陈锦平  李乃庆  李义华  李品蓉
作者单位:柳州市第三人民医院,柳州,545007
摘    要:目的通过测定肺心病患者的血浆纤维蛋白原(Fbg)功能,评价使用抗凝剂治疗肺心病的疗效。方法选择100例肺心病患者,随机分两组,研究组及对照组各50例,均按肺心病常规治疗。其中研究组加用抗凝剂低相对分子质量肝索(LMWH)5000u,皮下注射,1~2次/d,疗程7d。对比观察两组病例的Fbg功能在治疗前后的变化与临床转归的关系。结果研究组与对照组入院第1天测血浆Fbg功能水平与健康体检组比较均明显升高,检测结果:分别为7124±179 vs 2704±84,P〈0.01;7094±174 vs 2704±84,P〈0.01,差异均呈显著性。功能增强,最大光密度增大,反应数率增大,反应延滞时间缩短,提示整个Fbg功能增强。治疗后,血浆Fbg功能明显下降,其中加用抗凝剂的研究组比未加用抗凝剂的对照组下降幅度更大,3.744±91 vs 4.864±113,P〈0.05,差异有统计学意义。并且研究组患者慢支发作缓解快、住院时间明显缩短,其平均住院天数比对照组缩短2.2d。结论对肺心病患者常规测定并评估Fbg水平,有助于对患者进行危险分层及制定治疗方案,在常规治疗基础上对高Fbg血症进行干预,采取有效的抗凝治疗措施;对加快临床症状的缓解,缩短住院日,减少总费用具有重要意义。

关 键 词:肺心病  纤维蛋白原功能  抗凝剂
文章编号:1009-6213(2007)06-261-03
收稿时间:2007-07-20
修稿时间:2007年7月20日

The Fibrinogen Function Appraisal Heart Disease from Lung Disorders and Resistance Clotting's Curative Effect Studies
ZHU Ming-xia,LIU Hai-liang,LIU Da-ying,ZHOU Jin-gang,ZHONG Yan,PENG Jia,CHEN Jin-ping,LI Nai-qing,LI Yi-huaThe Third People's Hospital,Luzhou ,China.The Fibrinogen Function Appraisal Heart Disease from Lung Disorders and Resistance Clotting''''s Curative Effect Studies[J].Chinese Journal of Thrombosis and Hemostasis,2007,13(6):261-263.
Authors:ZHU Ming-xia  LIU Hai-liang  LIU Da-ying  ZHOU Jin-gang  ZHONG Yan  PENG Jia  CHEN Jin-ping  LI Nai-qing  LI Yi-huaThe Third People's Hospital  Luzhou  China
Institution:ZHU Ming-xia,LIU Hai-liang,LIU Da-ying,ZHOU Jin-gang,ZHONG Yan,PENG Jia,CHEN Jin-ping,LI Nai-qing,LI Yi-huaThe Third People's Hospital,Luzhou 545007,China
Abstract:Objective The goal through the determination heart disease from lung disorders patient' s blood plasma fibrinogen (Fbg) function, the appraisal resistance clotting' s the curative effect from heart disease of lung disorders. Methods Chooses 100 example heart disease from lung disorders patient, divides two groups stochastically; the study group and control group each 50 examples, the entire of heart disease from lung disorders conventional treated. Study team adds with anticoagulant low molecular weight heparin 5 000 u, hypodermic injection, 1 N 2 freqency/d, treatment course been 7 days. Results the study group and the control group are hospitalized first day to measure the blood plasma Fbg function level compare the healthy physical examination group quite are obviously rise , the examination result: Respectively is 712 ± 179 vs 270 ± 84, P 〈 0.01 ; 709 ± 174 vs 270 ± 84, P 〈 0.01, has significance difference, the function strengthens, the biggest light density increases, responded the number rate increases, responded the lagging time reduces, prompts the entire fibrinogen function enhancement. After the treatment, the blood plasma Fbg function drops obviously, in which adds with the anticoagulant study team drop scope is bigger than has not added with the anticoagulant control group; 3.74 ±91 vs 4.86 ± 113, P 〈 0.05, the difference has statistics significance. And the study team patients rae alleviated quickly; in hospital time quickly reduce obviously, its average in hospital number of days reduces for 2.2 days compared to the control group. Conclusion Determines to heart disease from lung disorders patient checked fibrinogen (Fbg) function, and appraised the Fbg level, is helpful in project on the dangerous lamination and the treatment plan to the patient, project on the intervention in the conventional treatment foundation to the high Fbg blood sickness, takes the effective anticoagulant remedial measure ; speeds up the clinical symptom, reduces in hospital date, reduces the total
Keywords:Heart disease from lung disorders  Fibrinogen function Anticoagulant
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号